VPBT Performance — ProFund VP Biotechnology
Data updated: 2026-08-28
VPBT returned +29.02% year to date and +89.37% over one year to Jun 2026. Annualised returns are +22.67% over 3 years and +12.26% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $185, against $138 for the category, and to $189 over one year, against $137. Volatility over the past three years was 25.57% a year. In the 12 months to Jun 2026 the fund lost a net $2.2M, and assets reached $48.82M.
VPBT Growth of $100
What $100 invested in ProFund VP Biotechnology grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | VPBT | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $189 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $185 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $178 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $259 | $182 |
VPBT Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +29.02% |
| 1 year | +89.37% |
| 3 years (annualised) | +22.67% |
| 5 years (annualised) | +12.26% |
VPBT Annual Returns
Calendar-year total returns of ProFund VP Biotechnology, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +29.02% |
| 2025 | +34.03% |
| 2024 | −0.16% |
| 2023 | +10.15% |
| 2022 | −7.71% |
| 2021 | +15.74% |
| 2020 | +15.37% |
| 2019 (Jul–Dec) | +10.64% |
VPBT Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.2% | +2.0% | +0.1% | +2.8% | +4.0% | +15.6% | — | — | — | — | — | — |
| 2025 | +2.7% | −4.4% | −8.8% | +2.3% | −4.8% | +4.6% | +3.1% | +4.8% | +11.4% | +12.5% | +9.1% | −0.8% |
| 2024 | −2.1% | +12.4% | −3.5% | −11.2% | +5.2% | +4.1% | +6.7% | +2.2% | −2.5% | −2.0% | +2.6% | −9.7% |
| 2023 | +0.3% | −4.2% | −1.8% | +5.3% | +4.9% | −1.2% | +1.1% | −6.0% | −7.7% | −9.5% | +14.0% | +18.2% |
| 2022 | −9.4% | −2.3% | +5.4% | −9.5% | +1.8% | −1.6% | +4.0% | −5.7% | −2.9% | +9.2% | +8.1% | −2.9% |
| 2021 | +5.4% | −1.8% | −0.5% | +4.3% | −0.3% | +6.3% | +3.5% | +4.3% | −7.1% | 0.0% | −2.0% | +3.3% |
| 2020 | −6.4% | +0.7% | −3.1% | +13.4% | +7.0% | +1.2% | +0.1% | −0.9% | −2.2% | −6.2% | +10.9% | +1.7% |
| 2019 | — | — | — | — | — | — | −4.3% | −0.9% | −0.1% | +6.6% | +8.9% | +0.5% |
VPBT Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 25.57%
- 3-year Sharpe ratio: 0.71 (vs 4.5% risk-free rate)
- Best month: +18.16% (Dec 2023)
- Worst month: −11.17% (Apr 2024)
VPBT Fund Flows
Monthly money in and out of ProFund VP Biotechnology, from SEC Form N-PORT.
- 12-month net flow: −$2.2M
- 12-month gross sales (incl. reinvestments): $50.9M
- Sales ÷ redemptions: 0.96×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $3.2M | $2.6M | $574K |
| May 2026 | $910K | $1.7M | −$820K |
| Apr 2026 | $1.9M | $4.0M | −$2.1M |
| Mar 2026 | $1.6M | $3.7M | −$2.1M |
| Feb 2026 | $961K | $1.8M | −$871K |
| Jan 2026 | $7.5M | $5.7M | $1.7M |
| Dec 2025 | $5.8M | $6.1M | −$358K |
| Nov 2025 | $2.1M | $1.3M | $823K |
| Oct 2025 | $2.0M | $2.6M | −$560K |
| Sep 2025 | $1.7M | $2.4M | −$755K |
| Aug 2025 | $11.3M | $8.9M | $2.4M |
| Jul 2025 | $12.0M | $12.1M | −$165K |
VPBT Assets Under Management
Net assets of ProFund VP Biotechnology by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $48.82M |
| 2026-03-31 | $41.74M |
| 2025-12-31 | $41.18M |
| 2025-09-30 | $33.88M |
| 2025-06-30 | $29.06M |
| 2025-03-31 | $29.83M |
| 2024-12-31 | $36.15M |
| 2024-09-30 | $42.30M |
| 2024-06-30 | $42.18M |
| 2024-03-31 | $46.39M |
| 2023-12-31 | $45.11M |
| 2023-09-30 | $39.33M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.